Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
- MACD is crossing MACD signal line at 0.6. MACD crossing signal line is bullish signal.
| MarketCap | 287.5B |
|---|---|
| PE Ratio | 45.0 |
| PEG Ratio | 1.9 |
| P/B | 28.8 |
| P/S (ttm) | 8.2 |
| Earning Growth (QoQ) | -7% |
| Revenue Growth (QoQ) | |
| Short % | 1% |
| Held by Institutions % | 84% |
| 1 Day Vol Adjusted Return | 0.6 |
| 1 Month Vol Adjusted Return | 4.1 |
| 3 Month Vol Adjusted Return | 15.3 |
| 6 Month Vol Adjusted Return | 9.1 |
| 20 Days SMA Price ZScore | 1.8 |
| 50 Days SMA Price ZScore | 1.2 |
| 12 -26 Days PPO | 0.7 |
| 1 Month Average Short Volume Ratio | 44.5 |
| 1 Day Volume Change ZScore | -0.6 |
| 1 Month Daily Vol | 2.1 |
Stock news
Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations at the American Diabetes Association's 82nd Scientific Sessions. The webcast will begin at 11:30 a.m. Eastern time and remarks will focus on results from the tirzepatide SURMOUNT-1 clinical trial, as well as Lilly's once-weekly basal insulin and early-phase incretins.
An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier. The U.S. Preventive Services Task Force (USPSTF) last addressed the issue in 2012, finding insufficient evidence to assess routine screening for CKD in asymptomatic adults.
The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.
The Dow Jones Industrial Average rallied Monday, as the stock market looked to rebound from last week's heavy losses. VMware surged on Broadcom talks.
Dow Jones futures rose, but be wary after the stock market suffered another week of solid losses as fears grew of a "hard" economic landing.
Another week of big losses as Wall Street adjusts to a "hard" reality. Tesla broke decisively, but it wasn't alone.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. The positive opinion was based on Lilly's Phase 3 BRAVE-AA1 and BRAVE-AA2 trials. Read Next: Eli Lilly's Olumia
The opinion marks the first step toward European regulatory approval of the oral JAK inhibitor for the treatment of adults with severe alopecia areata.
Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.